- Report
- May 2024
- 138 Pages
Global
From €6122EUR$6,499USD£5,235GBP
- Report
- June 2024
- 200 Pages
Global
From €7489EUR$7,950USD£6,404GBP
- Report
- January 2022
- 60 Pages
Global
From €3721EUR$3,950USD£3,182GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1884EUR$2,000USD£1,611GBP
- Report
- January 2024
- 83 Pages
Global
From €3500EUR$3,980USD£3,098GBP
- Report
- September 2022
- 90 Pages
Global
From €1884EUR$2,000USD£1,611GBP
Diphtheria is an infectious disease caused by the bacterium Corynebacterium diphtheriae. Treatment of diphtheria is primarily achieved through the administration of antibiotics, such as penicillin, erythromycin, and cephalosporins. Vaccination is also an important part of prevention and control of the disease.
The diphtheria drug market is a segment of the infectious diseases drugs market. It is composed of a range of products, including antibiotics, vaccines, and other treatments. These products are used to treat and prevent diphtheria, as well as to reduce the risk of complications associated with the disease.
The diphtheria drug market is highly competitive, with a number of companies offering products for the treatment and prevention of diphtheria. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Show Less Read more